Envestnet Asset Management Inc. Acquires 195,502 Shares of AstraZeneca PLC (NASDAQ:AZN)

Envestnet Asset Management Inc. boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 5.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,743,066 shares of the company's stock after acquiring an additional 195,502 shares during the quarter. Envestnet Asset Management Inc. owned 0.12% of AstraZeneca worth $275,115,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Banque Transatlantique SA acquired a new position in AstraZeneca during the fourth quarter worth $26,000. Confluence Investment Management LLC bought a new position in AstraZeneca during the first quarter valued at about $27,000. Mascagni Wealth Management Inc. bought a new position in AstraZeneca during the fourth quarter valued at about $29,000. FNY Investment Advisers LLC bought a new position in AstraZeneca during the first quarter worth about $29,000. Finally, Highline Wealth Partners LLC boosted its position in AstraZeneca by 447.4% during the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock worth $31,000 after purchasing an additional 340 shares during the period. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

AZN has been the subject of a number of research reports. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday. BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $89.00.

AstraZeneca Price Performance

AZN traded down $0.68 on Friday, reaching $71.13. The company had a trading volume of 2,729,851 shares, compared to its average volume of 5,270,319. The business has a 50 day simple moving average of $70.72 and a 200 day simple moving average of $70.78. The company has a market cap of $220.60 billion, a price-to-earnings ratio of 28.57, a P/E/G ratio of 1.32 and a beta of 0.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same period in the previous year, the firm earned $2.06 earnings per share. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. As a group, sell-side analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.